The sequence data sets supporting the results of this article are available in the DDBJ Sequence Read Archive under accession number DRA005849.

Introduction {#sec001}
============

DNA methylation is a key epigenetic modification that is involved in various cellular processes, including cell differentiation, transposon silencing, genomic imprinting, and carcinogenesis \[[@pgen.1007042.ref001],[@pgen.1007042.ref002]\]. This covalent epigenetic modification normally occurs at the C5 position of the cytosine (C) ring. In most mammalian cell types, the product of this modification, 5-methylcytosine (5mC), almost exclusively occurs in a CG context (CG methylation). However, non-CG methylation exists in certain cells such as oocytes \[[@pgen.1007042.ref003]--[@pgen.1007042.ref005]\], brain cells \[[@pgen.1007042.ref006]\], and embryonic stem cells (ESCs) \[[@pgen.1007042.ref007],[@pgen.1007042.ref008]\].

CG methylation is dynamically reprogrammed during mammalian gametogenesis and preimplantation development. In mouse germ cell development, CG methylation is first erased in primordial germ cells, partly due to the low expression of UHRF1 (Ubiquitin-like with PHD and RING finger domains 1) \[[@pgen.1007042.ref009]\], a factor that is essential for maintenance methylation at CG sites \[[@pgen.1007042.ref010],[@pgen.1007042.ref011]\] (see below). The hydroxylation of 5mC also plays a role in removing CG methylation through active or passive demethylation, particularly at the imprinting control regions (ICRs) \[[@pgen.1007042.ref012],[@pgen.1007042.ref013]\], which dictate the parental-origin-specific expression of the imprinted genes in somatic cells \[[@pgen.1007042.ref014]\]. Subsequently, in the female germline, an oocyte-specific methylation pattern is established in GOs by a *de novo* DNA methyltransferase (DNMT) complex composed of DNMT3A and DNMT3L \[[@pgen.1007042.ref004],[@pgen.1007042.ref005],[@pgen.1007042.ref015]--[@pgen.1007042.ref017]\]. *De novo* methylation continues until the fully grown oocyte (FGO) stage, with the genome of the oocyte accumulating both CG methylation and non-CG methylation \[[@pgen.1007042.ref003]--[@pgen.1007042.ref005]\]. It is known that the highly methylated regions in oocytes correspond to the actively transcribed regions \[[@pgen.1007042.ref004],[@pgen.1007042.ref018],[@pgen.1007042.ref019]\], which are marked by histone H3 lysine 36 trimethylation (H3K36me3) \[[@pgen.1007042.ref020]\]. Since DNMT3A recognizes H3K36me3 through its PWWP domain \[[@pgen.1007042.ref021]\], the enzyme appears to methylate regions that are premarked with this modification. *De novo* methylation in oocytes also requires histone replacement, since the disruption of the H3.3 chaperone HIRA results in a global reduction in CG methylation \[[@pgen.1007042.ref022]\].

After fertilization, with the exception of certain regions such as the ICRs and a subset of retrotransposons, the gamete-specific methylation patterns are globally erased \[[@pgen.1007042.ref004],[@pgen.1007042.ref023]\]. Notably, the paternal genome undergoes 5mC hydroxylation, followed by active or passive demethylation \[[@pgen.1007042.ref024]--[@pgen.1007042.ref027]\]. Several factors, including ZFP57, TRIM28, DPPA3, and maintenance-type DNA methyltransferase DNMT1 are required for maintaining CG methylation at the ICRs \[[@pgen.1007042.ref028]--[@pgen.1007042.ref033]\] against the wave of hydroxylation-dependent and hydroxylation-independent demethylation. In a study using oocyte-specific *Dnmt1* knockout (KO) mice, we previously reported that, although DNMT1 is mainly localized in the cytoplasm, a small amount of oocyte-derived maternal DNMT1 in the cell nucleus engages in CG maintenance methylation at the ICRs in preimplantation embryos \[[@pgen.1007042.ref031]\].

Mouse UHRF1 is a multi-domain protein that is essential for the CG maintenance methylation in proliferating somatic cells \[[@pgen.1007042.ref010],[@pgen.1007042.ref011]\]. The conventional KO of *Uhrf1* results in an embryonic lethal phenotype, which is accompanied by global genomic hypomethylation \[[@pgen.1007042.ref010]\]. UHRF1 contains five major protein domains: an ubiquitin-like (UBL) domain, a tandem Tudor domain (TTD), a plant homeodomain (PHD) finger, a SET and RING associated (SRA) domain, and a really interesting new gene (RING) finger \[[@pgen.1007042.ref034]--[@pgen.1007042.ref036]\]. UHRF1 recognizes hemimethylated CG sites through its SRA domain \[[@pgen.1007042.ref037]--[@pgen.1007042.ref039]\], and ubiquitinates H3K18 and H3K23 via the E3 ubiquitin ligase activity of its RING finger \[[@pgen.1007042.ref040],[@pgen.1007042.ref041]\]. Subsequently, DNMT1 recognizes H3K18 and/or other ubiquitinated lysine residues and methylates the unmodified C of hemimethylated CG sites to copy the existing methylation patterns. In addition, the TTD and PHD finger of this protein recognize H3K9me2/me3 \[[@pgen.1007042.ref035],[@pgen.1007042.ref036],[@pgen.1007042.ref042],[@pgen.1007042.ref043]\] and unmodified H3R2 \[[@pgen.1007042.ref044],[@pgen.1007042.ref045]\], respectively, suggesting their roles in the proper localization of this protein.

Unlike DNMT1, however, the role of UHRF1 during oogenesis and preimplantation development has not been explored. We therefore generated oocyte-specific *Uhrf1* conditional KO mice and examined the impact on DNA methylation in oocytes and preimplantation embryos. Our study revealed an expected role of maternal UHRF1 in preimplantation embryos and an unexpected new function in GOs.

Results {#sec002}
=======

The subcellular localization of UHRF1 in oocytes and preimplantation embryos {#sec003}
----------------------------------------------------------------------------

To reveal the role of UHRF1 proteins in mouse oocytes and preimplantation embryos, we first examined the expression and subcellular localization of UHRF1 by immunostaining. Like DNMT1 \[[@pgen.1007042.ref031]\], UHRF1 was mainly localized in the cytoplasm of GOs and preimplantation embryos ([Fig 1A and 1B](#pgen.1007042.g001){ref-type="fig"}). However, a weaker signal was detected in the nucleus. To examine the timing of the zygotic activation of the *Uhrf1* and *Dnmt1* genes, we reprocessed published polyA(+) mRNA-seq data from F1 hybrid embryos \[[@pgen.1007042.ref046]\], where expressed alleles could be distinguished based on the presence of single nucleotide polymorphisms (SNPs). While the levels of maternal *Uhrf1* and *Dnmt1* mRNAs had decreased by the 16-cell stage, the total levels of both mRNAs increased after this stage ([S1 Fig](#pgen.1007042.s001){ref-type="supplementary-material"}). The *Uhrf1* and *Dnmt1* mRNAs, which were derived from the paternal allele, were first detected at the mid 2-cell stage ([S1 Fig](#pgen.1007042.s001){ref-type="supplementary-material"}), pinpointing the timing of the zygotic activation of these genes.

![Expression and subcellular localization of UHRF1 in oocytes and preimplantation embryos.\
(A,B) Immunostaining of C57BL/6J developing oocytes (A), zygote to blastocyst stage embryos (B), *Uhrf1* KO oocytes (C), and *Uhrf1* mat-KO embryos (D) performed with an anti-UHRF1 antibody (Th-10a \[green\]). Each experiment was done with at least two batches of oocytes/embryos, and the total number of oocytes/embryos examined at each stage exceeded 20. The cell nucleus was counterstained with DAPI (blue). NGO, \<20 μm; GO, 20--50 μm; FGO, \>70 μm. Scale bar, 20 μm.](pgen.1007042.g001){#pgen.1007042.g001}

We generated oocyte-specific *Uhrf1* KO mice carrying a *zona pellucida glycoprotein 3* (*Zp3*)-Cre transgene \[*Uhrf1*^2lox/2lox^, *Zp3*-Cre\] ([S2A and S2B Fig](#pgen.1007042.s002){ref-type="supplementary-material"}). The *Zp3*-Cre transgene is expressed exclusively in GOs \[[@pgen.1007042.ref047]\]. No significant defects were observed in the morphology, size, or number of *Uhrf1* KO \[*Uhrf1*^1lox/1lox^\] FGOs ([S2C Fig](#pgen.1007042.s002){ref-type="supplementary-material"}). As expected, virtually no *Uhrf1* mRNA (by a quantitative reverse transcription-polymerase chain reaction; qRT-PCR) or UHRF1 protein (by Western blotting) was detected in the KO FGOs ([S2D and S2E Fig](#pgen.1007042.s002){ref-type="supplementary-material"}). The predicted truncated protein (amino acid 1--133) was not expressed, as its coding exons (2--3) were not detected at the mRNA level ([S2D Fig](#pgen.1007042.s002){ref-type="supplementary-material"}), probably due to nonsense-mediated mRNA decay \[[@pgen.1007042.ref048]\]. The loss of UHRF1 protein was confirmed by immunostaining as early as the non-growing oocyte (NGO) stage ([Fig 1C](#pgen.1007042.g001){ref-type="fig"} and [S2F Fig](#pgen.1007042.s002){ref-type="supplementary-material"}). The expression of *Dnmt1* was not affected by the *Uhrf1* KO ([S2E Fig](#pgen.1007042.s002){ref-type="supplementary-material"}). When *Uhrf1* KO oocytes were fertilized with wild-type sperm *in vitro* (*in vitro* fertilization, IVF), only 20% of the embryos (*Uhrf1* maternal-KO or mat-KO \[*Uhrf1*^1lox/+^\]) developed to the expanded blastocyst stage ([S3A Fig](#pgen.1007042.s003){ref-type="supplementary-material"}), suggesting that maternal UHRF1 plays a critical role in preimplantation development. This phenotype was much more severe than that of *Dnmt1* mat-KO \[*Dnmt1*^1lox/+^\] embryos \[[@pgen.1007042.ref031],[@pgen.1007042.ref032]\] ([S3A Fig](#pgen.1007042.s003){ref-type="supplementary-material"}). Virtually no UHRF1 protein was detected by immunostaining even in the surviving embryos ([Fig 1D](#pgen.1007042.g001){ref-type="fig"}).

Interestingly, while the absence of DNMT1 did not affect the subcellular localization of UHRF1, the absence of UHRF1 clearly decreased the level of DNMT1 in the nucleus of FGOs ([Fig 2A](#pgen.1007042.g002){ref-type="fig"}). The absence of maternal UHRF1 also decreased the level of nuclear DNMT1 in 2-cell embryos ([Fig 2B](#pgen.1007042.g002){ref-type="fig"}), suggesting that the nuclear localization of DNMT1 is dependent on UHRF1.

![Dependence of nuclear localization of DNMT1 on UHRF1.\
(A,B) Immunostaining of control \[*Uhrf1*^2lox/2lox^ or *Dnmt1*^2lox/2lox^\], *Uhrf1* KO, and *Dnmt1* KO FGOs (A) and control \[*Uhrf1*^2lox/+^ or *Dnmt1*^2lox/+^\], *Uhrf1* mat-KO, and *Dnmt1* mat-KO 2-cell embryos (B) was performed with anti-UHRF1 antibodies (green) or anti-DNMT1 antibodies (red). The nuclear/cytoplasmic signal ratios (N/C) were calculated using the mean signal intensities obtained by linear scanning across the cells. Each experiment was done with at least two batches of oocytes/embryos, and the total number (n) of oocytes/embryos is indicated. Each box indicates the 25--75 percentile and the bar in each box indicates the median. Asterisk, *P* \<0.01 (Mann-Whitney *U* test).](pgen.1007042.g002){#pgen.1007042.g002}

The role of maternal UHRF1 in the CG maintenance methylation in preimplantation embryos {#sec004}
---------------------------------------------------------------------------------------

In preimplantation embryos, both the paternal and maternal genomes are globally demethylated, while the ICRs and certain retrotransposons (such as intracisternal A particle \[IAP\] elements) retain CG methylation \[[@pgen.1007042.ref004],[@pgen.1007042.ref023],[@pgen.1007042.ref031],[@pgen.1007042.ref049],[@pgen.1007042.ref050]\]. To examine whether the maternal UHRF1 proteins play a role in CG maintenance methylation in these sequences, whole genome bisulfite sequencing (WGBS) was performed with control \[*Uhrf1*^2lox/+^\], *Uhrf1* mat-KO, and *Dnmt1* mat-KO blastocysts generated by IVF. Only well-developed *Uhrf1* mat-KO blastocysts were pooled ([S3A Fig](#pgen.1007042.s003){ref-type="supplementary-material"}, indicated as expanded) and subjected to the analysis. Since KO females were of the C57BL/6J background (*Mus musculus domesticus*) and the wild-type sperm was from JF1 males (*Mus musculus molossinus*), the parental alleles were distinguishable where SNPs were available. We used the post-bisulfite adaptor tagging (PBAT) method, which was amplification-free and applicable to a limited amount of DNA, to construct the WGBS libraries \[[@pgen.1007042.ref051]\].

Our WGBS with replicate samples basically confirmed good reproducibility, but the *Uhrf1* mat-KO blastocysts showed a lower correlation, likely due to slight differences in developmental stage and extremely low levels of CG methylation, which are sensitive to small variations ([S1](#pgen.1007042.s008){ref-type="supplementary-material"} and [S2](#pgen.1007042.s009){ref-type="supplementary-material"} Tables and [S4 Fig](#pgen.1007042.s004){ref-type="supplementary-material"}). The global CG methylation levels of the control, *Uhrf1* mat-KO, and *Dnmt1* mat-KO blastocysts were 14.3%, 3.5%, and 5.7%, respectively ([Fig 3A](#pgen.1007042.g003){ref-type="fig"} and [S2 Table](#pgen.1007042.s009){ref-type="supplementary-material"}, combined replicate data). Thus, the absence of maternal UHRF1 reduced the level of global CG methylation to one-fourth of the control level. The fact that the global methylation decreased by more than 50% suggests that not only the maternal genome but also the paternal genome, which was derived from the wild-type sperm, was affected after fertilization. Indeed, this was confirmed by the allele-specific methylation analysis using SNPs (see later). The loss of CG methylation was milder in *Dnmt1* mat-KO blastocysts. The non-CG methylation level was basically unaffected by the absence of either maternal UHRF1 or maternal DNMT1 ([S2 Table](#pgen.1007042.s009){ref-type="supplementary-material"}).

![The role of maternal UHRF1 in CG maintenance methylation in preimplantation embryos.\
(A) Violin plots showing the distribution of the 10-kb genomic regions with different CG methylation levels in control \[*Uhrf1*^2lox/+^\], *Uhrf1* mat-KO, and *Dnmt1* mat-KO blastocysts. The horizontal bars indicate the mean CG methylation levels. (B) The genomic distribution of CG methylation across chromosome 14 in control and mat-KO blastocysts. The CG methylation levels of 1-Mb windows are shown. GC contents, RefSeq genes, and CGIs are shown at the bottom. (C) The correlations between the CG methylation levels of the 10-kb genomic windows in the control and mat-KO blastocysts. (D) The CG methylation levels of respective portions of the genic regions, intergenic regions, and various repetitive sequences in control and mat-KO blastocysts. (E) The CG methylation levels of the ICRs in control and mat-KO blastocysts.](pgen.1007042.g003){#pgen.1007042.g003}

The analysis of CG methylation in 1-megabase (Mb) or 10-kilobase (kb) windows revealed that the absence of maternal UHRF1 or DNMT1 caused a basically global and proportional decrease in CG methylation across the genome ([Fig 3B and 3C](#pgen.1007042.g003){ref-type="fig"} and [S3B Fig](#pgen.1007042.s003){ref-type="supplementary-material"}). The genic regions, intergenic regions, repetitive elements (including IAPs), and CpG islands (CGIs) were all affected ([Fig 3D](#pgen.1007042.g003){ref-type="fig"} and [S3C Fig](#pgen.1007042.s003){ref-type="supplementary-material"}). The expected allele-specific CG methylation was confirmed in 12 (ten maternally methylated and two paternally methylated) of the 15 ICRs examined in the control blastocysts ([S3D Fig](#pgen.1007042.s003){ref-type="supplementary-material"}); SNPs were not available for the rest of the ICRs. As we reported previously \[[@pgen.1007042.ref031]\], the level of CG methylation was decreased to half that of the control blastocysts at the ICRs in *Dnmt1* mat-KO blastocysts. In contrast, the CG maintenance methylation at the ICRs was more severely affected in *Uhrf1* mat-KO blastocysts, to less than one-fourth the level observed in the control blastocysts ([Fig 3E](#pgen.1007042.g003){ref-type="fig"} and [S3D Fig](#pgen.1007042.s003){ref-type="supplementary-material"}). The loss of methylation from both parental genomes in mat-KO blastocysts indicates a role for maternal Uhrf1 in the maintenance of CG methylation.

The role of UHRF1 in *de novo* CG methylation during oocyte growth {#sec005}
------------------------------------------------------------------

We next examined whether this protein has any effect on CG methylation in FGOs. We therefore performed WGBS with control \[*Uhrf1*^2lox/2lox^\] and *Uhrf1* KO FGOs ([S1](#pgen.1007042.s008){ref-type="supplementary-material"} and [S2](#pgen.1007042.s009){ref-type="supplementary-material"} Tables and [S4 Fig](#pgen.1007042.s004){ref-type="supplementary-material"}). We found that the global CG methylation level was 30.8% in *Uhrf1* KO FGOs, which was 7.9% lower in comparison to control FGOs (38.7%) ([Fig 4A](#pgen.1007042.g004){ref-type="fig"} and [S2 Table](#pgen.1007042.s009){ref-type="supplementary-material"}). This was surprising as no DNA replication occurs during oocyte growth (meiotic prophase I), during which only *de novo* methylation is observed. Since the CG methylation level in NGOs was reported to be 2.3% \[[@pgen.1007042.ref005]\], these results suggested that UHRF1 was required for approximately one-fourth of the total increase in CG methylation ([Fig 4A](#pgen.1007042.g004){ref-type="fig"}). We previously reported that the slight decrease in CG methylation in *Dnmt1* KO FGOs (36.0% global CG methylation level compared to 38.7% in the control FGOs) ([Fig 4A](#pgen.1007042.g004){ref-type="fig"} and [S2 Table](#pgen.1007042.s009){ref-type="supplementary-material"}) could be explained by increased hemimethylation \[[@pgen.1007042.ref005]\]. Although the proportion of hemimethylated sites among the highly methylated CG sites was 6.1% greater in *Uhrf1* KO FGOs (12.9%) than it was in *Dnmt1* KO FGOs (6.8%) ([S5A Fig](#pgen.1007042.s005){ref-type="supplementary-material"}) (see [Materials and Methods](#sec009){ref-type="sec"}), this difference was not sufficient to explain the decrease in CG methylation that was observed in the *Uhrf1* KO FGOs.

![The role of UHRF1 in *de novo* CG methylation during oocyte growth.\
(A) Violin plots showing the distribution of the 10-kb genomic regions with different CG methylation levels in NGOs \[[@pgen.1007042.ref005]\], GOs (P12 and P15) \[[@pgen.1007042.ref053]\], and control \[*Uhrf1*^2lox/2lox^\], *Dnmt1* KO, and *Uhrf1* KO FGOs. The horizontal bars indicate the mean CG methylation levels. (B) The genomic distribution of CG methylation across chromosome 14 in control and KO FGOs. The CG methylation levels of the 1-Mb windows are shown. GC contents, RefSeq genes, and CGIs are shown at the bottom. (C) The correlations between the CG methylation levels of the 10-kb genomic windows in control and KO FGOs. (D) The CG methylation levels of respective portions of the genic regions, intergenic regions, and various repetitive sequences in control and respective KO FGOs. (E) The CG methylation levels of the ICRs in control and KO FGOs.](pgen.1007042.g004){#pgen.1007042.g004}

We previously reported that, in FGOs, nearly 65% of all 5mCs occurred at non-CG sites \[[@pgen.1007042.ref005]\]. This was confirmed in our control FGOs ([S5B Fig](#pgen.1007042.s005){ref-type="supplementary-material"} and [S2 Table](#pgen.1007042.s009){ref-type="supplementary-material"}) and, surprisingly, non-CG methylation was decreased to 85% of the level of control FGOs in *Uhrf1* KO FGOs ([S5B--S5D Fig](#pgen.1007042.s005){ref-type="supplementary-material"} and [S2 Table](#pgen.1007042.s009){ref-type="supplementary-material"}). This corresponded to a 0.6% reduction in non-CG methylation on a per site basis (from 3.2% to 2.6%) ([S2 Table](#pgen.1007042.s009){ref-type="supplementary-material"}). *Dnmt1* KO FGOs showed an increased non-CG methylation level, possibly due to the compensatory upregulation of *Dnmt3a* \[[@pgen.1007042.ref005]\]. With regard to the sequence context, the CHG and CHH sites (where H represents the base A, C, or T) were equally affected ([S5B Fig](#pgen.1007042.s005){ref-type="supplementary-material"}). These results strongly suggest that UHRF1 plays a role in *de novo* CG and non-CG methylation, not only through the recognition of hemimethylated CG sites, but also through an unknown mechanism.

To examine whether any regions of the genome are preferred for the *de novo* CG methylation involving UHRF1, we determined the CG methylation levels in 1-Mb windows and found that the levels in *Uhrf1* KO FGOs decreased across the genome in comparison to control FGOs ([Fig 4B](#pgen.1007042.g004){ref-type="fig"} and [S6A Fig](#pgen.1007042.s006){ref-type="supplementary-material"}). However, subsequent analyses in 10-kb windows revealed that the loss of CG methylation was most remarkable in genomic regions that showed moderate levels of CG methylation ([Fig 4C](#pgen.1007042.g004){ref-type="fig"}). In addition, there was a positive correlation between the losses in CG and non-CG methylation in the 10-kb genomic windows ([S6B Fig](#pgen.1007042.s006){ref-type="supplementary-material"}). Various repetitive elements, including IAPs, were moderately affected ([Fig 4D](#pgen.1007042.g004){ref-type="fig"}). Many CGIs were known to be methylated in FGOs \[[@pgen.1007042.ref049]\] and, again, moderately methylated CGIs were the most affected in *Uhrf1* KO FGOs ([S6C Fig](#pgen.1007042.s006){ref-type="supplementary-material"}). In contrast, the maternally methylated ICRs, which represent the most highly methylated regions in the FGO genome, were only slightly affected by the absence of UHRF1, except the *Gnas1A*, *Peg10*, and *Mest* ICRs, which showed significant reduction in CG methylation (p = 6.49 x 10^−121^, 1.85 x 10^−41^, and 2.68 x 10^−81^, respectively; kai-squared test) ([Fig 4E](#pgen.1007042.g004){ref-type="fig"}).

UHRF1 facilitates *de novo* methylation in inactive regions during late oocyte growth {#sec006}
-------------------------------------------------------------------------------------

As a first step to understand how UHRF1 is involved in *de novo* CG and non-CG methylation in oocytes, we attempted to explore the features of the regions affected in *Uhrf1* KO FGOs in greater detail. We first identified the genomic regions (10-kb windows) with a CG methylation level of ≥40% in control FGOs and divided them into four groups: moderately (40--80%) methylated regions that were unaffected (decrease \<20%) by *Uhrf1* KO (Group 1); moderately methylated regions that were affected (decrease ≥20%) by KO (Group 2); highly (≥80%) methylated regions that were unaffected by KO (Group 3); highly methylated regions that were affected by KO (Group 4) ([Fig 5A](#pgen.1007042.g005){ref-type="fig"} and [S3 Table](#pgen.1007042.s010){ref-type="supplementary-material"}). Of the moderately methylated regions (Groups 1 and 2), 35% of the cases were affected (Group 2) but, in contrast, only 9% of the highly methylated regions (Groups 3 and 4) were affected (Group 4) ([Fig 5A](#pgen.1007042.g005){ref-type="fig"}), confirming that the moderately methylated regions were preferentially affected.

![UHRF1 facilitates *de novo* methylation in inactive regions during late oocyte growth.\
(A) The classification of the 10-kb genomic regions that were moderately (40--80%) or highly (≥80%) methylated in the control FGOs, based on the extent of methylation change (≥20% or not) in *Uhrf1* KO FGOs (Groups 1--4). The right panel shows the proportion of moderately and highly methylated 10-kb regions belonging to each group. (B) The distribution of the transcript levels (RPKM) and H3K36me3 enrichment levels \[[@pgen.1007042.ref020]\] (corrected read count) of the 10-kb regions belonging to each group. The bar in each box indicates the median value. (C) Differences in CG methylation across the transcribed regions between control and *Uhrf1* KO FGOs. The transcribed regions were classified into four categories based on the expression levels (RPKM) in control FGOs and the results for the respective groups are shown separately. (D) The changes in CG methylation occurring in the three different stages of oocyte growth were determined for the 10-kb regions of the respective groups.](pgen.1007042.g005){#pgen.1007042.g005}

Transcription-coupled *de novo* CG methylation is predominant in oocytes \[[@pgen.1007042.ref004],[@pgen.1007042.ref018],[@pgen.1007042.ref019]\]. To examine the relationship between transcription and UHRF1-dependent *de novo* CG methylation, we performed RNA-seq with replicate samples from control \[*Uhrf1*^2lox/2lox^\] and *Uhrf1* KO FGOs ([S4 Table](#pgen.1007042.s011){ref-type="supplementary-material"}). Overall, the transcription profiles of these FGOs were very similar (R = 0.969, combined replicate data, [S6D Fig](#pgen.1007042.s006){ref-type="supplementary-material"}), and we confirmed that the highly methylated regions produced more transcripts ([Fig 5B](#pgen.1007042.g005){ref-type="fig"}). Also, using previously published H3K36me3 chromatin immunoprecipitation-sequencing data from GOs (≥30--65 μm) \[[@pgen.1007042.ref020]\], we found that the highly methylated regions were preferentially marked with this transcription-coupled histone mark \[[@pgen.1007042.ref052]\] ([Fig 5B](#pgen.1007042.g005){ref-type="fig"}). We then examined the CG methylation changes in *Uhrf1* KO FGOs in the transcribed regions and found that untranscribed or only lowly transcribed regions were the most severely affected ([Fig 5C](#pgen.1007042.g005){ref-type="fig"}).

Lastly, we used the published WGBS data from NGOs collected at the newborn stage \[[@pgen.1007042.ref005]\] and GOs collected on postnatal days 12 (P12) and P15 \[[@pgen.1007042.ref053]\] to examine the timing of *de novo* CG methylation in affected and unaffected regions. In comparison to the regions that were unaffected by *Uhrf1* KO (Groups 1 and 3), the affected regions gained less methylation in the early phase of oocyte growth (between newborn NGO and P12 GO) and underwent greater methylation in the later phase (between P15 GO to FGO) ([Fig 5D](#pgen.1007042.g005){ref-type="fig"}). Interestingly, the three maternally methylated ICRs more affected by *Uhrf1* KO (the *Gnas1A*, *Peg10*, and *Mest* ICRs) compared to others ([Fig 4E](#pgen.1007042.g004){ref-type="fig"}) also gained more methylation in the later phase ([S6E Fig](#pgen.1007042.s006){ref-type="supplementary-material"}). These results indicate that UHRF1 accelerates *de novo* CG methylation in untranscribed or lowly transcribed regions during the late stage of oocyte growth.

The relative contribution to *de novo* CG methylation and maintenance CG methylation {#sec007}
------------------------------------------------------------------------------------

Since UHRF1 was found to be involved in *de novo* CG (and non-CG) methylation in GOs, we attempted to determine what proportion of the loss of CG methylation in *Uhrf1* mat-KO blastocysts ([Fig 3](#pgen.1007042.g003){ref-type="fig"}) was explained by the *de novo* activity and what proportion was explained by the maintenance activity. The *de novo* activity only affects the maternal genome, while the maintenance activity affects both parental genomes: we therefore determined the CG methylation level of each parental genome in control and *Uhrf1* mat-KO blastocysts using SNPs. In the control blastocysts, the CG methylation level of the maternal genome was 14.3%, which was 2.3% lower than that in the paternal genome (16.6%) ([S7A Fig](#pgen.1007042.s007){ref-type="supplementary-material"}). (The observed levels were lower than those of the inner cell mass cells (20% and 21% for the maternal and paternal genome, respectively) \[[@pgen.1007042.ref050]\], perhaps because trophectoderm cells display lower methylation.) In *Uhrf1* mat-KO blastocysts, the CG methylation levels of the maternal and paternal genomes were decreased to 3.1% and 4.5%, respectively ([S7A Fig](#pgen.1007042.s007){ref-type="supplementary-material"}). (Since SNP-associated CG sites were more frequently found in the genic regions, where the CG methylation level was high, the average CG methylation level detected in the parental genomes (3.8%) was slightly higher than that in the whole genome (3.5%).)

The CG methylation level in control and *Uhrf1* KO FGOs was 38.7% and 30.8%, respectively ([S2 Table](#pgen.1007042.s009){ref-type="supplementary-material"}). These levels correspond to those of the maternal genome at the time of fertilization. Since the methylation level of the maternal genome was 14.3% in control blastocysts (see above), this genome undergoes a ×0.37 (14.3%/38.7%) methylation change, mainly due to replication-coupled dilution during preimplantation development ([S7B Fig](#pgen.1007042.s007){ref-type="supplementary-material"}). (Hydroxylation-dependent demethylation selectively occurs on the paternal genome \[[@pgen.1007042.ref024]--[@pgen.1007042.ref027]\].) If there was no maternal effect caused by oocyte-specific *Uhrf1* KO and if we apply the demethylation rate determined above to the maternal genome derived from *Uhrf1* KO FGOs, then the expected methylation level would be 11.4% (= 30.8% ×0.37) ([S7B Fig](#pgen.1007042.s007){ref-type="supplementary-material"}). Thus, the *de novo* activity would account for 2.9% (= 14.3%--11.4%) of the total methylation loss of the maternal genome (11.2% \[= 14.3%--3.1%\]) in *Uhrf1* mat-KO blastocysts). The rest of the loss (8.3% \[= 11.2%--2.9%\]) would be attributable to the maintenance activity in preimplantation embryos ([S7B Fig](#pgen.1007042.s007){ref-type="supplementary-material"}). Although the precise values may be subject to variations between the samples ([S4 Fig](#pgen.1007042.s004){ref-type="supplementary-material"}), these results show that the loss of CG methylation in the *Uhrf1* mat-KO blastocysts can largely be explained by the loss of the maintenance activity in early embryos.

Discussion {#sec008}
==========

In the present study, we found that the UHRF1 produced in oocytes has an important role in shaping the DNA methylation landscape in oocytes and preimplantation embryos. We first showed that, like DNMT1 \[[@pgen.1007042.ref031]\], UHRF1 is mainly, but not exclusively, localized in the cytoplasm during oocyte growth and preimplantation development. Why should epigenetic regulators, which in most cases exert their function in the nucleus, exist in the cytoplasm during this period? For DNMT1, a few studies have addressed the mechanism of cytoplasmic localization in early embryos \[[@pgen.1007042.ref054]\]; however its function in the cytoplasm is still unknown. Furthermore, CG maintenance methylation and other events that are known to involve UHRF1 (for example, DNA repair \[[@pgen.1007042.ref055]--[@pgen.1007042.ref057]\]) occur in the nucleus and thus the biological significance of cytoplasmic UHRF1 remains to be clarified. As expected, however, a small amount of UHRF1 did exist in the nucleus of oocytes and early embryos, as did DNMT1 \[[@pgen.1007042.ref031]\]. Interestingly, the nuclear localization of DNMT1 was dependent on UHRF1, as oocyte-specific *Uhrf1* KO resulted in a greatly reduced DNMT1 signal in the nucleus. A previous study in ESCs showed that DNMT1 recruitment to specific target loci, but not nuclear localization, is dependent on UHRF1 \[[@pgen.1007042.ref010],[@pgen.1007042.ref011]\]. Thus, the nuclear entry and/or retention of DNMT1 is regulated differently in different cell types.

*Uhrf1* mat-KO embryos showed partial preimplantation lethality, a phenotype that is much more severe than that of *Dnmt1* mat-KO embryos. Our WGBS showed that the global CG methylation level is more greatly reduced in *Uhrf1* mat-KO blastocysts (×0.25 in comparison to control blastocysts) than it is in *Dnmt1* mat-KO blastocysts (×0.36 in comparison to control). The loss of CG methylation at the ICRs and IAP elements in the *Dnmt1* mat-KO embryos was approximately ×0.50 (see also \[[@pgen.1007042.ref031]\]); however, the loss in *Uhrf1* mat-KO embryos was greater (×0.25 or less). These results strongly suggest that maternal UHRF1 is essential for imprint maintenance and IAP repression in preimplantation embryos. It is known that the repressed alleles of the ICRs and IAP elements are marked with H3K9me3 in ESCs and preimplantation embryos \[[@pgen.1007042.ref058],[@pgen.1007042.ref059]\]. These results suggest that UHRF1 may be recruited to specific targets through H3K9me3 recognition via its TTD \[[@pgen.1007042.ref035],[@pgen.1007042.ref036],[@pgen.1007042.ref042],[@pgen.1007042.ref043]\]. However, mice expressing a mutated UHRF1 protein with a defective TTD exhibit normal viability/fertility with an only \~10% reduction in CG methylation \[[@pgen.1007042.ref060]\]. Thus, the mechanism through which UHRF1 is recruited to the targets (particularly the ICRs and IAP elements) in the preimplantation embryos remains an open question.

An unexpected discovery of the present study was the involvement of UHRF1 in *de novo* CG and non-CG methylation in GOs. We previously reported that DNMT1 is important for the completion of *de novo* CG methylation in oocytes: DNMT1 appears to act on the hemimethylated CG sites left behind during the *de novo* methylation process and make them fully methylated \[[@pgen.1007042.ref005]\]. UHRF1 may contribute to this process by efficiently recognizing hemimethylated CG sites since the proportion of hemimethylated CG sites among the highly methylated sites was increased in *Uhrf1* KO FGOs. This increase in hemimethylated CG sites was greater than that observed in *Dnmt1* KO FGOs. Unexpectedly, but consistent with the above-mentioned findings, we found that not only CG methylation, but also non-CG methylation, was affected in *Uhrf1* KO FGOs. Thus we speculate that UHRF1 may be directly involved in *de novo* CG and non-CG methylation, which are both mediated by the DNMT3A-DNMT3L complex in GOs \[[@pgen.1007042.ref005]\].

Since UHRF1 can interact with DNMT3A and DNMT3B in ESCs and silence exogenous promoters \[[@pgen.1007042.ref061]\], it may interact with these enzymes in oocytes as well and facilitate *de novo* methylation. Interestingly, however, UHRF1 only played a limited role in the establishment of CG methylation at the maternally methylated ICRs: rather, the protein was important for *de novo* CG and non-CG methylation in the moderately methylated genomic regions. These regions were mostly untranscribed, lacked H3K36me3 marking, and tended to be *de novo* methylated in a late stage of oocyte growth. Interestingly, among the maternally methylated ICRs, those that were less resistant to UHRF1 depletion normally gained CG methylation in the late stage of oocyte growth. At present, the mechanism through which UHRF1 is recruited to these regions and through which it engages in *de novo* CG and non-CG methylation remains to be elucidated.

In conclusion, our study showed the importance of maternal UHRF1 in CG maintenance methylation during preimplantation development and in *de novo* CG and non-CG methylation in transcriptionally inactive regions during oocyte growth. To the best of our knowledge, this is the first study to show the involvement of UHRF1 in *de novo* methylation *in vivo*. We believe that our findings give further insight into the epigenetic reprogramming in early development and provide a basis for further improvements in reproductive technologies and regenerative medicine.

Materials and methods {#sec009}
=====================

Ethics statement {#sec010}
----------------

Mouse husbandry and all of the mouse experiments were carried out under the ethical guidelines of Kyushu University. The mice were euthanized by carbon dioxide asphyxiation. The protocols were approved by the Institutional Animal Care and Use Committee of Kyushu University.

KO mice {#sec011}
-------

We generated ESCs carrying a loxP site in intron 3 and a neomycin selection cassette flanked by loxP sites in intron 5 of *Uhrf1* \[*Uhrf1*^3lox/+^\]. *Uhrf1*^3lox/+^ mice were obtained by chimera formation and germline transmission. Because the *Uhrf1*^3lox/3lox^ males were infertile, we crossed females of this genotype with EIIA-Cre males \[[@pgen.1007042.ref062]\] to remove the neomycin cassette and generated *Uhrf1*^2lox/+^ mice. *Uhrf1*^2lox/2lox^ mice were crossed with mice carrying the *Zp3*-Cre transgene \[[@pgen.1007042.ref047]\] to generate oocyte-specific *Uhrf1* KO mice \[*Uhrf1*^2lox/2lox^, *Zp3*-Cre\]. The oocyte-specific *Dnmt1* KO mice \[*Dnmt1*^2lox/2lox^, *Zp3*-Cre\] have been described previously \[[@pgen.1007042.ref031],[@pgen.1007042.ref063]\]. The mice were genotyped by PCR under standard conditions using the primers listed in [S5 Table](#pgen.1007042.s012){ref-type="supplementary-material"}. All of the KO mice were basically of the C57BL/6J background (*Mus musculus domesticus*).

Oocyte collection, IVF, and embryo culture {#sec012}
------------------------------------------

NGOs and GOs were obtained from the ovaries on P10. FGOs were obtained from the ovaries at 8--12 weeks. Preimplantation embryos were obtained by IVF. Females aged ≥8 weeks were injected with 7.5 U of pregnant mare serum gonadotropin; 48 h later, they were injected with 7.5 U of human chorionic gonadotropin to induce super ovulation. Cumulus-oocyte complexes were collected from the oviduct and fertilized with C57BL/6J sperm for immunostaining and Western blotting or with JF1 (*Mus musculus molossinus*) sperm for WGBS. Cumulus cells were carefully removed by washing with phosphate-buffered saline (PBS), and fertilized embryos were cultured in KSOM medium (EmbryoMax KSOM Medium (1X) w/ 1/2 Amino Acids, Merck Millipore) at 37°C with 5% CO~2~.

Western blotting {#sec013}
----------------

Twenty FGOs were lysed in a sample buffer (62.5 mM Tris-HCl (pH 6.8), 0.5× PBS, 2% SDS, 10% glycerol, and 5% 2-mercaptoethanol) and sonicated. Proteins were denatured by heating at 95°C for 5 min, separated by electrophoresis on a 10% SDS polyacrylamide gel, and transferred onto a nitrocellulose membrane (Amersham). The blots were blocked with 5% skimmed milk, incubated with anti-UHRF1 rabbit polyclonal antibody (M-132, Santa Cruz), anti-DNMT1 rabbit polyclonal antibody (a kind gift from Shoji Tajima), or anti-β-actin mouse monoclonal antibody (AC-15, Santa Cruz) (1:10,000 dilution each). After several washes, the blots were incubated with HRP-conjugated anti-rabbit or mouse IgG antibody (1:10,000 dilution), and detected using Chemi-Lumi One Ultra reagent (11644--40, Nacalai Tesque) and an LAS-3000 lumino-image analyzer (Fujifilm).

Immunostaining {#sec014}
--------------

Embryos and oocytes were fixed with 4% paraformaldehyde in PBS at room temperature for 30 min and washed with PBS three times. After incubation with a pretreatment buffer (1% bovine serum albumin and 2% Triton-X100 in PBS) at room temperature for 15 min, the embryos and oocytes were incubated at 4°C overnight with anti-UHRF1 rat monoclonal (Th-10a, MBL) antibody (1:500 dilution) or anti-DNMT1 rabbit polyclonal antibody (1:1000 dilution). After washing three times, the embryos and oocytes were incubated with fluorescence-labeled secondary antibody (1:1000 dilution) at room temperature for 30 min. The secondary antibody was CF488 donkey anti-rabbit IgG (H+L) antibody (20015, Biotium Inc), CF488A donkey anti-rat IgG (H+L) antibody (20027, Biotium Inc), or CF594 donkey anti-rabbit IgG (H+L) antibody (20152, Biotium Inc). After washing three times, oocytes and embryos were mounted in VECTASHIELD medium with DAPI (Vector Laboratory) and observed using an LSM510 or LSM700 confocal laser scanning microscope (Carl Zeiss) with a 63× objective lens and a 10× ocular lens. The signal intensities were measured using the ZEN 2012 (blue edition) software program (Carl Zeiss). The nuclear/cytoplasmic signal ratios were calculated using the mean nuclear and cytoplasmic signal intensities.

The qRT-PCR {#sec015}
-----------

Total RNA was extracted from 100 FGOs using AllPrep DNA/RNA Mini kit (QIAGEN) and reverse transcribed using a PrimeScript RT reagent kit with gDNA Eraser (TaKaRa). A qRT-PCR was carried out using a KAPA SYBR Fast qPCR kit (Kapa Biosystems) in Thermal Cycler Dice Real Time System Single (TaKaRa) in accordance with the manufacturer\'s protocol. The primers that were used are listed in [S5 Table](#pgen.1007042.s012){ref-type="supplementary-material"}. The relative gene expression was quantified using the comparative cycle threshold method, with the *Gapdh* expression used for normalization.

WGBS and the data analysis {#sec016}
--------------------------

WGBS libraries were prepared using the PBAT method as described in our previous reports \[[@pgen.1007042.ref005],[@pgen.1007042.ref051],[@pgen.1007042.ref064]\]. Five hundred to 1,000 oocytes or 30--40 blastocysts were spiked with 0.1 ng of lambda phage DNA (Promega) and subjected to bisulfite conversion. The concentrations of the PBAT libraries were measured by a qPCR using a KAPA Illumina Library Quantification kit (Kapa Biosystems). Cluster generation and sequencing were performed in a single-read mode using a TruSeq SR Cluster kit v3-cBot-HS (Illumina) and TruSeq SBS kit v3-HS (Illumina) according to manufacturer's protocols. The libraries were sequenced on a HiSeq 2500 or HiSeq 1500 equipped with HCS v2.0.5 and RTA v1.17.20 (suitable for WGBS) \[[@pgen.1007042.ref065]\] to generate 101-nucleotide single-end reads. We trimmed the raw sequence reads to 96 bases by removing the adapter sequences from the 5' end and one base from the 3' end. The resulting reads were aligned to the reference mouse genome (mm10) using Bismark v0.14.2 \[[@pgen.1007042.ref066]\]. The seed length was 28, the maximum number of mismatches permitted in the seed was 1, and the "---pbat" option was selected. Only uniquely aligned reads were analyzed. We estimated the bisulfite conversion rate using reads that were uniquely aligned to the lambda phage genome (accession no. J02459). The sequences and information of the chromosomes, RefSeq genes, CGIs, and repetitive elements were downloaded from the UCSC genome browser \[[@pgen.1007042.ref067]\]. Throughout this paper, the global CG methylation levels refer to the weighted levels, which take the sequencing depth into account \[[@pgen.1007042.ref068]\].

Estimating the frequency of hemimethylated CG sites {#sec017}
---------------------------------------------------

The proportion of hemimethylated sites among the highly methylated CG sites was estimated as previously described \[[@pgen.1007042.ref005]\]. In brief, we selected CG sites with a methylation level of ≥70% on either strand that showed a read depth of ≥10. The CG sites with a significant difference in methylation (Fisher's exact test, p \<0.05) were defined hemimethylated.

RNA-seq and the data analysis {#sec018}
-----------------------------

Total RNA was extracted from 30 oocytes. Whole transcript amplification and library construction were performed as described previously \[[@pgen.1007042.ref069]\]. The libraries were sequenced on a HiSeq 2000 to generate 50-nucleotide single-end reads. We trimmed the raw sequence reads by removing poly-A tails and low quality bases from the 3' end. The resulting sequences were aligned to the reference mouse genome (mm10) using the TopHat software program (v2.0.14) \[[@pgen.1007042.ref070]\]. We used a gtf file of published oocyte transcripts \[[@pgen.1007042.ref019]\] for mapping. The mapped reads were counted using featureCounts \[[@pgen.1007042.ref071]\] to calculate the reads per kb per million mapped reads (RPKM) values.

Accession numbers {#sec019}
-----------------

The sequence data sets supporting the results of this article are available in the DDBJ Sequence Read Archive under accession number DRA005849.

Supporting information {#sec020}
======================

###### The expression of *Uhrf1* and *Dnmt1* mRNAs in preimplantation embryos.

The expression of *Uhrf1* and *Dnmt1* mRNAs from the maternal and paternal alleles was analyzed separately using published data from (CAST/EiJ × C57BL/6J) F1 hybrid embryos (GSE45719) \[[@pgen.1007042.ref046]\]. An enlarged view of the *Uhrf1* and *Dnmt1* expression from the zygote to the late 4-cell stage is shown on the right. The expression levels are shown by the RPKM values. Error bar, standard error.

(EPS)

###### 

Click here for additional data file.

###### The establishment of oocyte-specific *Uhrf1* KO mice.

\(A\) A schematic representation of the genomic organization of the wild-type (WT), 2lox, and 1lox *Uhrf1* alleles. The filled boxes indicate the protein-coding regions. (B) The predicted domain architecture of the WT and mutated UHRF1 proteins. The immunogen used to generate the anti-UHRF1 antibody M-132 (used for Western blotting) is shown. (C) The morphology of control \[*Uhrf1*^2lox/2lox^\] and *Uhrf1* KO FGOs. Scale bar, 100 μm. (D) The expression of *Uhrf1* and the *Dnmt* family mRNAs in control and *Uhrf1* KO FGOs was measured by qRT-PCR. Two portions of *Uhrf1* mRNA were amplified for quantification. The expression of *Gapdh* was used for normalization. (E) The detection of UHRF1 and DNMT1o proteins in control and *Uhrf1* KO FGOs by Western blotting using M-132 and anti-DNMT1 antibodies. β-actin was used as a loading control. (F) The immunostaining signal intensities obtained with an anti-UHRF1 antibody (Th-10a) in control and *Uhrf1* KO developing oocytes.

(EPS)

###### 

Click here for additional data file.

###### CG methylation in *Uhrf1* mat-KO blastocysts.

\(A\) The morphology of control \[*Uhrf1*^2lox/+^\], *Dnmt1* mat-KO, and *Uhrf1* mat-KO embryos at 96 h after IVF. Among the *Uhrf1* mat-KO embryos, those that developed to the expanded blastocyst stage are shown on the left. Only well-developed blastocysts were used for WGBS. Scale bar, 100 μm. (B) The genomic distribution of CG methylation across all chromosomes in the control and mat-KO blastocysts. The CG methylation levels of the 1-Mb windows are shown. (C) The correlations between the CG methylation levels of the CGIs in control and mat-KO blastocysts. (D) Allele-specific CG methylation at the ICRs in control and *Uhrf1* mat-KO blastocysts.

(EPS)

###### 

Click here for additional data file.

###### Reproducibility of WGBS data between replicates.

The correlations of the CG methylation levels of the biological replicates were examined in 10-kb genomic windows.

(EPS)

###### 

Click here for additional data file.

###### CG and non-CG methylation in *Uhrf1* KO FGOs.

\(A\) The proportions of hemimethylated sites among highly methylated CG sites in control \[*Uhrf1*^2lox/2lox^\], *Dnmt1* KO, and *Uhrf1* KO FGOs. (B) The proportion of 5mCs in all Cs in each sequence context. H represents the base A, C, or T. (C) Violin plots showing the distribution of the 10-kb genomic regions with different non-CG methylation levels in control \[*Uhrf1*^2lox/+^\], *Dnmt1* KO, and *Uhrf1* KO FGOs. The horizontal bars indicate the mean non-CG methylation levels. (D) The correlation between the non-CG methylation levels of the 10-kb genomic windows in the control and KO FGOs.

(EPS)

###### 

Click here for additional data file.

###### Genomic regions showing impaired *de novo* CG and non-CG methylation in *Uhrf1* KO FGOs.

\(A\) The genomic distribution of CG methylation across all chromosomes in control \[*Uhrf1*^2lox/2lox^\] and *Uhrf1* KO FGOs. The CG methylation levels of the 1-Mb windows are shown. (B) Box plots showing the correlation between the impact of *Uhrf1* KO on CG and non-CG methylation in the 10-kb windows. (C) The correlation between the CG methylation levels of CGIs in control and *Uhrf1* KO FGOs. (D) The correlation between the (RPKM+1) values in control and *Uhrf1* KO FGOs. (E) The CG methylation levels of the ICRs in NGOs, P15 GOs, and FGOs.

(EPS)

###### 

Click here for additional data file.

###### The contribution of the UHRF1 produced in oocytes to *de novo* CG methylation and maintenance CG methylation.

\(A\) The levels of CG methylation in the respective parental genomes in control \[*Uhrf1*^2lox/+^\], *Dnmt1* mat-KO and *Uhrf1* mat-KO blastocysts. (B) The contribution of UHRF1 produced in oocytes to *de novo* CG methylation in GOs and maintenance methylation in preimplantation embryos.

(EPS)

###### 

Click here for additional data file.

###### Sequencing and mapping summary of WGBS.

(PDF)

###### 

Click here for additional data file.

###### Number of methylated cytosines.

(PDF)

###### 

Click here for additional data file.

###### Criteria for Group 1--4 regions.

(PDF)

###### 

Click here for additional data file.

###### Sequencing and mapping summary of RNA-seq.

(PDF)

###### 

Click here for additional data file.

###### List of PCR primers.

(PDF)

###### 

Click here for additional data file.
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